Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 4/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640094 | 0.93 | PYCR1 (0.55) | PYCR1IDO1LOXL2MAOBMAOA | |
| SCHEMBL15544000 | 0.82 | MAOB (0.61) | MAOB | |
| SCHEMBL1311590 | 0.75 | TAAR1 (0.50) | PYCR1IDO1LOXL2MAOBMAOA | |
| SCHEMBL18244863 | 0.74 | IDO1 (0.46) | PYCR1IDO1LOXL2MAOBTAAR1 | |
| SCHEMBL5249523 | 0.74 | PYCR1 (0.52) | PYCR1IDO1MAOBTAAR1AGXT | |
| SCHEMBL11196340 | 0.74 | TRPA1 (0.43) | PYCR1MAOB | |
| SCHEMBL96029 | 0.74 | TAAR1 (0.48) | PYCR1IDO1LOXL2MAOBTAAR1 | |
| SCHEMBL3633726 | 0.74 | MIF (0.52) | PYCR1IDO1LOXL2MAOBMAOA | |
| SCHEMBL1921131 | 0.74 | PYCR1 (0.50) | PYCR1IDO1MAOBTAAR1MIF | |
| SCHEMBL18770738 | 0.74 | PYCR1 (0.54) | PYCR1IDO1MAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | claimed |
| EP-2405973-B1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2015-04-22 | — | — | EP | claimed |
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2026104676-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114980886-B | Compounds and methods for treating oxalate-related diseases | 奥沙鲁克斯公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2022247676-A1 | COMPOUND WITH DIPYRROLOPYRIDINE STRUCTURE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 南京康屹生物医药中心(有限合伙) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022247676-A1 | COMPOUND WITH DIPYRROLOPYRIDINE STRUCTURE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 南京康屹生物医药中心(有限合伙) | 2022-12-01 | — | — | WO | disclosed |
| CN-115385911-A | Compound with dipyrrolopyridine structure, preparation method and medical application | 南京康屹生物医药中心(有限合伙) | 2022-11-25 | — | — | CN | disclosed |
| EP-1465878-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2004014366-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004007469-A1 | NEW ALKYNYLATED QUINAZOLIN COMPOUNDS AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | disclosed |
| WO-2003033478-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP9 | PYCR1 3628/4885IDO1 606/4885LOXL2 439/4885 |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | PYCR1 2288/4885IDO1 405/4885LOXL2 723/4885 |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | PYCR1 305/4885IDO1 1420/4885LOXL2 41/4885 |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | PYCR1 305/4885IDO1 1420/4885LOXL2 41/4885 |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, OAT | PYCR1 305/4885IDO1 1420/4885LOXL2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.